A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 10, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions

Diffuse Large B-cell Lymphoma With no Other Specification

Interventions

BIOLOGICAL

allogenic natural killer cells

OT-C001 will be administered by IV infusion weekly for at least 3 doses.

Trial Locations (1)

RECRUITING

Saint-Eloi Hospital, Montpellier